Cite
MLA Citation
K. Kannan et al.. “TAK-659, a dual SYK/FLT3 inhibitor, leads to complete and sustained tumor regression and immune memory against tumor cells upon combination with anti-PD-1 agent.” European journal of cancer, vol. 69, n.d., pp. S92–. http://access.bl.uk/ark:/81055/vdc_100039473366.0x00001e